Cassava Sciences, Inc. is a pioneering clinical-stage biotechnology company headquartered in Austin, Texas, focused on developing innovative therapies for neurodegenerative diseases, particularly Alzheimer's disease. Currently, the company is advancing its lead candidate, simufilam, through late-stage clinical trials, aiming to meet significant unmet needs in neurological treatment. By redefining therapeutic approaches and emphasizing patient outcomes, Cassava is strategically positioning itself to capitalize on growth opportunities within the competitive biotechnology sector, while striving to enhance the quality of life for patients affected by these debilitating conditions. Show more

Location: 6801 N. CAPITAL OF TEXAS HIGHWAY, AUSTIN, TX, UNITED STATES, 78731, Austin, TX, 78731, USA | Website: https://www.cassavasciences.com | Industry: BIOTECHNOLOGY | Sector: HEALTHCARE

Market Cap

142M

52 Wk Range

$1.15 - $4.98

Previous Close

$1.99

Open

$1.97

Volume

559,867

Day Range

$1.89 - $1.98

Enterprise Value

-9.947M

Cash

106.1M

Avg Qtr Burn

-6.221M

Insider Ownership

12.79%

Institutional Own.

28.50%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Simufilam Details Tuberous Sclerosis Complex (TSC)-related epilepsy	IND Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Simufilam (PTI-125) Details Alzheimer's disease	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.